06.04.15
Sylmar, Calif.-base Second Sight Medical Products Inc., which makes implantable visual prosthetics that provide functional vision to blind patients, today announced that Matthew J. Pfeffer, corporate vice president and chief financial officer of MannKind Corporation, has been appointed to its board of directors effective immediately. Pfeffer qualifies as a financial expert under U.S. Securities and Exchange Commission regulations.
“We are excited to welcome Matthew Pfeffer to the board and to draw on his expertise as a seasoned life sciences executive and leader in our industry as we work to build the market for the Argus II retinal prosthesis, advance our product pipeline, and build shareholder value,” said Robert Greenberg, M.D., Ph.D., president and CEO of Second Sight.
“Matthew Pfeffer will bring the same thoughtful financial leadership to Second Sight that he has delivered as Chief Financial Officer of MannKind,” said Alfred E. Mann, chairman of the board of directors of Second Sight and executive chairman of the board of directors of MannKind Corporation. “I am confident that he will make a meaningful and immediate contribution to our distinguished board of directors.”
Since 2008, Pfeffer has been corporate vice president and chief financial officer of MannKind Corporation. Previously, he served as chief financial officer and senior vice president of finance and administration of VaxGen Inc., with responsibility for finance, tax, treasury, human resources, information technology, purchasing and facilities functions. Prior to VaxGen, Pfeffer served as chief financial officer of Cell Genesys Inc. where during his nine-year tenure he served as director of finance before being named chief financial officer in 1998. He previously served in a variety of financial management positions at other companies, including roles as corporate controller, manager of internal audit, and manager of financial reporting. Pfeffer is a Certified Public Accountant and began his career at Price Waterhouse (now Pricewaterhouse Coopers).
“We are excited to welcome Matthew Pfeffer to the board and to draw on his expertise as a seasoned life sciences executive and leader in our industry as we work to build the market for the Argus II retinal prosthesis, advance our product pipeline, and build shareholder value,” said Robert Greenberg, M.D., Ph.D., president and CEO of Second Sight.
“Matthew Pfeffer will bring the same thoughtful financial leadership to Second Sight that he has delivered as Chief Financial Officer of MannKind,” said Alfred E. Mann, chairman of the board of directors of Second Sight and executive chairman of the board of directors of MannKind Corporation. “I am confident that he will make a meaningful and immediate contribution to our distinguished board of directors.”
Since 2008, Pfeffer has been corporate vice president and chief financial officer of MannKind Corporation. Previously, he served as chief financial officer and senior vice president of finance and administration of VaxGen Inc., with responsibility for finance, tax, treasury, human resources, information technology, purchasing and facilities functions. Prior to VaxGen, Pfeffer served as chief financial officer of Cell Genesys Inc. where during his nine-year tenure he served as director of finance before being named chief financial officer in 1998. He previously served in a variety of financial management positions at other companies, including roles as corporate controller, manager of internal audit, and manager of financial reporting. Pfeffer is a Certified Public Accountant and began his career at Price Waterhouse (now Pricewaterhouse Coopers).